References
- Green H, Paul M, Vidal L, Leibovici L. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev 2007;(3): CD005590.
- Calderon EJ. Pneumocystis infection: seeing beyond the tip of the iceberg. Clin Infect Dis 2010;50:354–356.
- Kelly MN, Shellito JE. Current understanding of Pneumocystis immunology. Future Microbiol 2010;5:43–65.
- Stringer JR, Beard CB, Miller RF. A new name (Pnemocystis jiroveci) for pneumocystis in humans. Emerg Infect Dis 2002;8:891–896.
- Kamel S, O'Connor S, Lee N, Filshie R, Nandurkar H, Tam CS. High incidence of Pneumocystis jirovecii pneumonia in patients receiving biweekly rituximab and cyclophosphamide, adriamycin, vincristine, and prednisone. Leuk Lymphoma 2010; 51:797–801.
- Venhuizen AC, Hustinx WN, van Houte AJ, Veth G, van der Griend R. Three cases of Pneumocystis jirovecii pneumonia (PCP) during first-line treatment with rituximab in combination with CHOP-14 for aggressive B-cell non-Hodgkin's lymphoma. Eur J Haematol 2008;80:275–276.
- Kolstad A, Holte H, Fosså A, Lauritzsen GF, Gaustad P, Torfoss D. Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen. Haematologica 2007;92:139–140.
- Wunderlich A, Kloess M, Reiser M, et al Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol 2003;14:881–893.
- Pfreundschuh M, Trümper L, Kloess M, et al Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004;104:634–641.
- Katsuya H, Suzumiya J, Sasaki H, et al Addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy has a high risk of developing interstitial pneumonia in patients with non-Hodgkin lymphoma. Leuk Lymphoma 2009;50:1818–1823.
- Pfreundschuh M, Zeynalova S, Poeschel V, et al Dose-dense rituximab improves outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL): results of the DENSE-R-CHOP-14 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNH). Blood 2007;110(Suppl. 1): (Abstract 789).
- Shelton E, Yong M, Cohney S. Late onset Pneumocystis pneumonia in patients receiving rituximab for humoral renal transplant rejection. Nephrology 2009;14:696–699.
- Gentner J, Morra M, Knutsen AP. Development of common variable immunodeficiency in an 8-year-old boy treated with rituximab for idiopathic thrombocytopenia. Pediatr Asthma Allergy Immunol 2008;21:99–104.
- Teichmann LL, Woenckhaus M, Vogel C, Salzberger B. Fatal Pneumocystis pneumonia following rituximab administration for rheumatoid arthritis. Rheumatology 2008;47:1256–1257.
- Delarue R, Haioun C, Ribrag V, et al R-CHOP14 compared to R-CHOP21 in elderly patients with diffuse large B-cell lymphoma: results of the interim analysis of the LNH03-6B GELA Study. Blood 2009;114(Suppl. 1): (Abstract 406).